164 related articles for article (PubMed ID: 23614618)
1. Molecular mechanisms underlying the role of microRNAs in resistance to epidermal growth factor receptor-targeted agents and novel therapeutic strategies for treatment of non-small-cell lung cancer.
Maftouh M; Avan A; Galvani E; Peters GJ; Giovannetti E
Crit Rev Oncog; 2013; 18(4):317-26. PubMed ID: 23614618
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.
Leonetti A; Assaraf YG; Veltsista PD; El Hassouni B; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Jan; 42():1-11. PubMed ID: 30544036
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs associated with therapy of non-small cell lung cancer.
Lu J; Zhan Y; Feng J; Luo J; Fan S
Int J Biol Sci; 2018; 14(4):390-397. PubMed ID: 29725260
[TBL] [Abstract][Full Text] [Related]
5. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
[TBL] [Abstract][Full Text] [Related]
6. From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer.
Formisano L; Jansen VM; Marciano R; Bianco R
Anticancer Agents Med Chem; 2018; 18(9):1235-1240. PubMed ID: 28901258
[TBL] [Abstract][Full Text] [Related]
7. The Role of MicroRNAs in Lung Cancer: Implications for Diagnosis and Therapy.
Naeli P; Yousefi F; Ghasemi Y; Savardashtaki A; Mirzaei H
Curr Mol Med; 2020; 20(2):90-101. PubMed ID: 31573883
[TBL] [Abstract][Full Text] [Related]
8. Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer.
Rolfo C; Fanale D; Hong DS; Tsimberidou AM; Piha-Paul SA; Pauwels P; Van Meerbeeck JP; Caruso S; Bazan V; Cicero G; Russo A; Giovannetti E
Curr Pharm Biotechnol; 2014; 15(5):475-85. PubMed ID: 24846062
[TBL] [Abstract][Full Text] [Related]
9. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing.
Kohsaka S; Petronczki M; Solca F; Maemondo M
Future Oncol; 2019 Feb; 15(6):637-652. PubMed ID: 30404555
[TBL] [Abstract][Full Text] [Related]
10. Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs.
Calvo E; Rowinsky EK
Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S35-42. PubMed ID: 15638956
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.
Rolfo C; Giovannetti E; Hong DS; Bivona T; Raez LE; Bronte G; Buffoni L; Reguart N; Santos ES; Germonpre P; Taron M; Passiglia F; Van Meerbeeck JP; Russo A; Peeters M; Gil-Bazo I; Pauwels P; Rosell R
Cancer Treat Rev; 2014 Sep; 40(8):990-1004. PubMed ID: 24953979
[TBL] [Abstract][Full Text] [Related]
12. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
[TBL] [Abstract][Full Text] [Related]
13. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
14. Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.
Sin TK; Wang F; Meng F; Wong SC; Cho WC; Siu PM; Chan LW; Yung BY
Int J Mol Sci; 2016 Feb; 17(2):237. PubMed ID: 26891293
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer: Minireview.
Tibaldi C; D'Incecco A; Lagana A
Anticancer Agents Med Chem; 2015; 15(6):694-700. PubMed ID: 25612681
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
17. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
18. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
Ma G; Zhu J; Liu F; Yang Y
DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
[TBL] [Abstract][Full Text] [Related]
19. Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma.
Prabhu VV; Devaraj N
J Environ Pathol Toxicol Oncol; 2017; 36(2):151-158. PubMed ID: 29199595
[TBL] [Abstract][Full Text] [Related]
20. Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies.
Barton S; Starling N; Swanton C
Curr Cancer Drug Targets; 2010 Dec; 10(8):799-812. PubMed ID: 20718710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
